Australia's largest stock trading and investment forum Australia's #1 stock forum

IMC immuron limited

11.9%

3.7¢

predictions?, page-13

First 13 Last

Share
Profile

Follow
Orioles

327 Posts.

7

29/03/18

15:56

Post #: 32124934
Share

Originally posted by Fact Finder ↑

Hi Marko2

When I read the document links that Orioles posted there was one which specifically dealt with the reduction on the basis of average times and it stated that the normal 3 years would be reduced to 18 months. The 62 months is on the basis of 3 years as I then read the table so it would come back to 44 months if 18 is right.

On the question of Breakthrough Therapy status as Orioles said this was the first time I had seen this term used in the context of Immuron.

Don't ask me where but in one of the many documents I read relating to Immuron I believe I read that 124 had been given 'orphan' status and as such if it progressed through Phase II successfully then the FDA could accelerate Phase III reducing the time in Phase III to about 18 months and then assuming it maintained the same safety profile it could be allowed to progress to Phase IV which would allow it to come to market with strict monitoring and reporting of its useage. In other words it would be being trialled effectively in the real world.

The time in Phase IV was referred to but I can not be sure now except that the total time if it was allowed this pathway by the FDA was still going to be 5 years to full unrestricted market access. The advantage of this being that Immuron earns revenue and the problems relating to recruitment I would suspect be diminished if not eradicated.

I also believe that having the 'orphan' status also importantly extended the period that Immuron could enforce its IP entitlements.

I have said this once before on here but possibly does not hurt to repeat. The valuation of Immuron is probably impossible at this stage and certainly I do not have the credentials to make even an informed guess.

So what I have mused upon is the valuation placed on Viralytics (VLA ASX) by Merck for the purpose of its takeover offer being half a billion dollars. If you look to the value of the addressable market just for 124 leaving aside all of the other things that Immuron has going for it 124 (fatty liver disease) and Cavatak (Cancer treatment & VLA's only drug) have very similar potential addressable market values.

What this means is that the present market value as calculated by Orioles of $80,000,000 AUS is 6.25 times less than the value placed on Viralytics by Merck.

6.25 x .38c is $2.375 to which you should add something for all of the other irons that Immuron has in the fire. This method of valuing Immuron could well be complete rubbish but I am happy with it for now (as I am with my present profit) and will keep holding until the true potential is realised.

It is obvious that I have the view that as has been said on here that the current market cap of Immuron seems ridiculously low.

Expand

Immuron's IMM-124E is intended as a a combination therapy drug. It would pair nicely with antifibrotics such as Intercept's Ocaliva or Allergan's Ceniciviroc.

Last edited by Orioles: 29/03/18

IMC Price at posting: 37.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RHC

Ramsay Health Care profit surges as Australian hospitals drive FY26 turnaround

AS2

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

KTA

Krakatoa Resources ramps up drilling at Zopkhito antimony and gold project in Georgia

TGN

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

CRR

Critical Resources and CSIRO to collaborate on DSD battery technology

First 13 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 3.7¢		Change -0.005(11.9%)		Mkt cap ! $13.71M

Open	High	Low	Volume
4.2¢	4.2¢	3.7¢	26.14K

Buyers (Bids)

Vol.	Price($)
118132	3.7¢

Sellers (Offers)

Price($)	Vol.
4.2¢	10874

Last trade - 16.00pm 27/08/2026 (20 minute delay)

IMC (ASX) Chart

predictions?, page-13

Ramsay Health Care profit surges as Australian hospitals drive FY26 turnaround

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

Krakatoa Resources ramps up drilling at Zopkhito antimony and gold project in Georgia

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

Critical Resources and CSIRO to collaborate on DSD battery technology

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

predictions?, page-13

Top Stories

Ramsay Health Care profit surges as Australian hospitals drive FY26 turnaround

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

Krakatoa Resources ramps up drilling at Zopkhito antimony and gold project in Georgia

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

Critical Resources and CSIRO to collaborate on DSD battery technology

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News